Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

rTMS for Apathy Clinical Trial

NCT: NCT05561205 · RECRUITING

NCT IDNCT05561205
StatusRECRUITING
Start Date2023-02-09
Completion2026-12-01

Brief Summary

Apathy is a common, early, and disabling symptom in dementias and mild behavioural impairment such as Alzheimer's disease (AD) and is characterized by lack of interest and enthusiasm. Both repetitive transcranial magnetic stimulation (rTMS), a form of non-invasive brain stimulation, and methylphenidate, a medication, have been shown to improve apathy. This pilot study will investigate rTMS as a treatment for apathy in neurocognitive disorders and mild behavioural impairment in individuals receiving methylphenidate and individuals not receiving medication for apathy.

Frequently Asked Questions

What is rTMS for Apathy Clinical Trial?

rTMS for Apathy Clinical Trial is a clinical trial registered under NCT05561205. Current status: RECRUITING.

What is the status of NCT05561205?

The current status of NCT05561205 (rTMS for Apathy Clinical Trial) is: RECRUITING.

When did rTMS for Apathy Clinical Trial start?

rTMS for Apathy Clinical Trial started on 2023-02-09.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.